In May 2026, Abbott secured both 510(k) clearance from the U.S. Food and Drug Administration and a CE mark in Europe for its latest AI-enabled coronary imaging platform, Ultreon 3.0, marking a meaningful step forward in precision cardiology.
At its core, Ultreon 3.0 integrates Optical Coherence Tomography with advanced AI to improve how clinicians assess plaque morphology and optimize stent selection and placement. Building on earlier versions, the platform enhances imaging clarity, accelerates processing speed, and delivers deeper clinical insights at the point of care.
OCT itself leverages infrared light to produce high-resolution images of vessel walls. Clinical evidence suggests that, compared to angiography-guided interventions, OCT can enable larger minimum stent areas, though without a statistically significant impact on long-term target vessel failure. Still, guidelines underscore OCT’s importance in lesion preparation and stent sizing, reinforcing its role in interventional workflows.
The integration of AI represents the real inflection point. Since receiving its first CE mark in 2021, Abbott has iteratively advanced the platform, culminating in this latest regulatory milestone. Ultreon 3.0’s high-speed, one-second pullback capability provides detailed cross-sectional imaging with minimal or no contrast, an important advantage given the association between contrast agents and kidney injury in certain patients.
From a systems perspective, the value proposition is twofold: improved clinical confidence and streamlined workflows. AI-driven automation supports real-time decision-making and post-procedural validation, aligning with the broader shift toward data-assisted interventions. As the principle “time is muscle” reminds us, faster and more precise treatment directly correlates with better patient outcomes.
Strategically, this innovation strengthens Abbott’s vascular portfolio, which reported 9.5% comparable growth in Q1, highlighting continued momentum at the intersection of medtech and AI.